Novo Nordisk B A/S
Novo Nordisk B A/S
1,57 %
350,00 DKK
5,40
Kurs
350,00
Høj
350,00
Ændring
1,57 %
Lav
343,75
Opdateret
21-08-2019
Åben
345,50
Nyheder om Novo Nordisk B A/S
Factsheet for Novo Nordisk B A/S
Company Profile
Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key Stats
Website: http://www.novonordisk.com
Headquarter country: Denmark
Employees: 36.000
Market Cap (at close 20-08-2019): DKK 816B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 18,90 21,60 17,30 31,30 26,50
Forward Price/Earnings 17,90 20,20 16,20 25,60 23,00
Price/Free Cash Flow 23,00 21,90 16,80 33,80 26,40
Return on Assets 36,20 38,20 40,10 41,30 35,90
Return on Equity 76,00 80,20 82,20 79,90 63,90
Return on Invested Capital 73,80 78,60 81,10 78,30 63,10
Dividend


Dividend/Share:7,90
Ex. Dividend Date:31-12-2018
Trailing Dividend Yield:2,35
Payout Ratio:52,04
Date Currency Amount
31-03-2019 DKK 5,15
30-09-2018 DKK 3,00
31-03-2018 DKK 4,85
30-09-2017 DKK 3,00
31-03-2017 DKK 4,60
30-09-2016 DKK 3,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 111.831,00 111.696,00 111.780,00 107.927,00 88.806,00
Gross Profit 94,21 94,06 94,60 91,74 74,24
Gross Margin % 84,25% 84,21% 84,63% 85,00% 83,60%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 53.295,00 51.952,00 51.056,00 46.509,00 37.570,00
Net income 38.628,00 38.130,00 37.925,00 34.860,00 26.481,00
Basic Earnings Per Share 15,96 15,42 14,99 13,56 10,10
Operating Income 47,25 48,97 48,43 49,44 34,49
Operating Margin % 42,25% 43,84% 43,33% 45,81% 38,84%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 44.616,00 41.168,00 48.314,00 38.287,00 31.692,00
Capital Expenditures -12.410,00 -8.648,00 -8.267,00 -6.406,00 -4.335,00
Free Cash Flow 32.206,00 32.520,00 40.047,00 31.881,00 27.357,00
Balance Sheet

Assets 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Current Assets 59.067,00 60.080,00 59.766,00 55.140,00 46.293,00 42.058,00
Long Term Assets 51.702,00 42.275,00 37.773,00 36.659,00 30.769,00 28.279,00
Total Assets 110.769,00 102.355,00 97.539,00 91.799,00 77.062,00 70.337,00
Liabilities 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Total Current Liabilities 54.164,00 47.056,00 47.436,00 40.873,00 33.689,00 24.225,00
Long Term Liabilities 4.834,00 3.957,00
Total Liabilities 52.270,00 44.830,00
Equity 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Retained Earnings 53.406,00 48.977,00 46.111,00 46.816,00 41.277,00 41.137,00
Treasury Stock 11,00 11,00 9,00 10,00 11,00 21,00
Total Stockholder Equity 51.839,00 49.815,00 45.269,00 46.969,00 40.294,00 42.569,00
Net Tangible Assets 46.694,00 46.490,00 42.555,00 44.811,00 38.916,00 40.954,00